IT Business Partner
ITF Therapeutics
IT Business Partner
ITF Therapeutics
Develops and commercializes rare-disease therapies
Reporting to: Senior Director, Head of IT
About This Role
ITF is seeking an experienced IT Business Partner to support General & Administrative (G&A) functions. Acting as the primary liaison between business stakeholders and IT, this individual will partner closely with Finance, Human Resources, and Legal teams to understand business priorities, recommend technology solutions, and coordinate the successful delivery of enterprise initiatives.
This role is focused on supporting U.S. operations while collaborating with global IT and business teams responsible for configuring and implementing enterprise systems. The ideal candidate combines strong business relationship management skills with experience supporting enterprise applications within a regulated Life Sciences environment.
What You’ll Do
Who You Are
You are a relationship-focused IT professional who partners effectively with Finance, HR, and Legal teams to understand business needs and deliver practical technology solutions. You excel at translating requirements into action, coordinating across global teams, and driving initiatives from planning through execution. With experience supporting enterprise applications in a regulated environment, you bring strong communication skills, sound judgment, and a continuous improvement mindset. You thrive in a collaborative, fast-paced organization and are viewed as a trusted partner by both business and IT stakeholders.
Required Skills and Experience:
Preferred Skills:
Additional Information:
The base compensation range for this role is: $190,000 - $225,000. Compensation is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics